Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.30 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2339664 | 1.00 | PDE4D (0.35) | PDE4DPDE4APDE4BPDE4CERN1 | |
| SCHEMBL2344026 | 0.93 | PDE4D (0.36) | PDE4DPDE4APDE4BPDE4CERN1 | |
| SCHEMBL2344839 | 0.90 | PDE4A (0.38) | PDE4DPDE4APDE4BPDE4CERN1 | |
| SCHEMBL2351811 | 0.90 | PDE4A (0.38) | PDE4DPDE4APDE4BPDE4CERN1 | |
| SCHEMBL1411523 | 0.89 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CERN1 | |
| SCHEMBL1414991 | 0.89 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CERN1 | |
| SCHEMBL2263071 | 0.87 | PDE4D (0.33) | PDE4DPDE4APDE4BPDE4CERN1 | |
| SCHEMBL2264343 | 0.87 | PDE4D (0.33) | PDE4DPDE4APDE4BPDE4CERN1 | |
| SCHEMBL3470263 | 0.83 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1411743 | 0.83 | PDE4D (0.44) | PDE4DPDE4APDE4BPDE4CERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257221-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257169-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-10-20 | — | — | US | disclosed |
| US-8003798-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | NYCOMED GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257221-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | PDE4D 4/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20110257169-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | PDE4D 4/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.